Show simple item record

dc.contributor.authorDurán, Verónica
dc.contributor.authorYasar, Hanzey
dc.contributor.authorBecker, Jennifer
dc.contributor.authorThiyagarajan, Durairaj
dc.contributor.authorLoretz, Brigitta
dc.contributor.authorKalinke, Ulrich
dc.contributor.authorLehr, Claus-Michael
dc.date.accessioned2019-09-16T13:48:36Z
dc.date.available2019-09-16T13:48:36Z
dc.date.issued2019-07-31
dc.identifier.citationNanomedicine. 2019 Jul 31;21:102073. doi: 10.1016/j.nano.2019.102073.en_US
dc.identifier.issn1549-9642
dc.identifier.pmid31376570
dc.identifier.doi10.1016/j.nano.2019.102073
dc.identifier.urihttp://hdl.handle.net/10033/621942
dc.description.abstractBiodegradable polymeric nanoparticles (NP) made from poly (lactid-co-glycolide) acid (PLGA) and chitosan (CS) hold promise as innovative formulations for targeted delivery. Since interactions of such NP with primary human immune cells have not been characterized, yet, here we assessed the effect of PLGA or CS-PLGA NP treatment on human peripheral blood mononuclear cells (PBMC), as well as on monocyte-derived DC (moDC). Amongst PBMC, antigen presenting cells (APC) showed higher uptake of both NP preparations than lymphocytes. Furthermore, moDC internalized CS-PLGA NP more efficiently than PLGA NP, presumably because of receptor-mediated endocytosis. Consequently, CS-PLGA NP were delivered mostly to endosomal compartments, whereas PLGA NP primarily ended up in lysosomes. Thus, CS-PLGA NP confer enhanced delivery to endosomal compartments of APC, offering new therapeutic options to either induce or modulate APC function and to inhibit pathogens that preferentially infect APC.en_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectChitosan-PLGA NPen_US
dc.subjectIntracellular traffickingen_US
dc.subjectMonocyte-derived DCen_US
dc.subjectNanoparticlesen_US
dc.subjectPBMCen_US
dc.subjectPLGA NPen_US
dc.titlePreferential uptake of chitosan-coated PLGA nanoparticles by primary human antigen presenting cells.en_US
dc.typeArticleen_US
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalNanomedicine: Nanotechnology, Biology, and Medicineen_US
refterms.dateFOA2019-09-16T13:48:36Z
dc.source.journaltitleNanomedicine : nanotechnology, biology, and medicine


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Durán et al.pdf
Size:
916.3Kb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International